81 results on '"Vicente-Vicente L"'
Search Results
2. Role of quercetin metabolites in the flavonoid?s protective effect against cisplatin nephrotoxicity
- Author
-
Muñoz-Reyes, D, primary, Casanova, A.G., additional, Tascón, J., additional, Vicente-Vicente, L, additional, López-Hernández, F.J., additional, Morales, A.I., additional, and Prieto Vicente, M., additional
- Published
- 2021
- Full Text
- View/download PDF
3. Pesticide exposure and risk of early kidney damage
- Author
-
Casanova, A.G., primary, Martín-Reina, J., additional, Vicente-Vicente, L., additional, Tascón, J., additional, Prieto, M., additional, Pescador, M., additional, Bautista, J.D., additional, Moreno, I., additional, and Morales, A.I., additional
- Published
- 2021
- Full Text
- View/download PDF
4. Revisión sistemática sobre nuevas estrategias en la prevención de la Nefropatía Inducida por Contrastes.
- Author
-
Collado-Medaña, C., Casanova, A. G., Vicente-Vicente, L., and Morales, A. I.
- Subjects
CONTRAST induced nephropathy ,ACUTE kidney failure ,CONTRAST media ,ISCHEMIC preconditioning ,DEVELOPING countries - Abstract
Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
5. Acute kidney injury predisposition induced by sub-nephrotoxic dosage of cisplatin disappears after 6 days
- Author
-
Casanova, A.G., primary, Vicente-Vicente, L., additional, Hernández-Sánchez, M.T., additional, Rihuete, M.I., additional, Nieto, R., additional, Ramis, L.M., additional, del Barco, E., additional, Gómez-Bernal, A., additional, Cruz, J.J., additional, Sancho, S.M., additional, Prieto, M., additional, Pescador, M., additional, López-Hernández, F.J., additional, and Morales, A.I., additional
- Published
- 2016
- Full Text
- View/download PDF
6. The European TOX-OER project: Learning toxicology through open educational resources
- Author
-
Vicente-Vicente, L., primary, Prieto, M., additional, Pescador, M., additional, Casanova, A.G., additional, Hernández-Sánchez, M.T., additional, and Morales, A.I., additional
- Published
- 2016
- Full Text
- View/download PDF
7. Proteinuria, albuminuria and KIM-1 as predictors of kidney damage associated with tobacco consumption
- Author
-
Vicente-Vicente, L., primary, Sanz-Parras, F.J., additional, Casanova-Paso, A.G., additional, Hernández-Sánchez, M.T., additional, Pescador, M., additional, Prieto, M., additional, and Morales, A.I., additional
- Published
- 2016
- Full Text
- View/download PDF
8. Kidney damage associated with tobacco consumption might be predicted with proteinuria, albuminuria and KIM-1
- Author
-
Hernández Sánchez, M.T., primary, Vicente Vicente, L., additional, Sanz Parras, F.J., additional, Casanova, A.G., additional, Pescador, M., additional, Prieto, M., additional, and Morales, A.I., additional
- Published
- 2016
- Full Text
- View/download PDF
9. Dosage interval of cisplatin-induced predisposition to acute kidney injury
- Author
-
Casanova, A.G., primary, Vicente Vicente, L., additional, Hernández Sánchez, M.T., additional, Rihuete, M.I., additional, Nieto, R., additional, Ramis, L.M., additional, Gómez Bernal, A., additional, Sancho, S.M., additional, Prieto, M., additional, Pescador, M., additional, López Hernández, F.J., additional, and Morales, A.I., additional
- Published
- 2016
- Full Text
- View/download PDF
10. Toxicology learning through the use of open educational resources: The European “TOX-OER” Project
- Author
-
Casanova, A.G., primary, Vicente Vicente, L., additional, Prieto, M., additional, Pescador, M., additional, Hernández Sánchez, M.T., additional, Almaraz Menéndez, F.E., additional, and Morales, A.I., additional
- Published
- 2016
- Full Text
- View/download PDF
11. Toxicology.0: An on-line course of introduction into toxicology discipline for master students
- Author
-
Casanova, A.G., primary, Hernández Sánchez, M.T., additional, Prieto, M., additional, Pescador, M., additional, Morales, A.I., additional, and Vicente Vicente, L., additional
- Published
- 2016
- Full Text
- View/download PDF
12. NGAL as a prospective biomarker of predisposition to acute kidney injury induced by sub-nephrotoxic contrast media
- Author
-
Hernández Sánchez, M.T., primary, Vicente Vicente, L., additional, Casanova, A.G., additional, Pescador, M., additional, Prieto, M., additional, López Hernández, F.J., additional, and Morales, A.I., additional
- Published
- 2016
- Full Text
- View/download PDF
13. Biomarkers for the prediction of acute kidney injury: Is canonical biplot analyses a useful tool?
- Author
-
Pescador, M., primary, Ramos, M., additional, Arias, M., additional, Gómez-Alamillo, C., additional, Sánchez-Barba, M., additional, Quiros, Y., additional, Blanco-Gozalo, V., additional, Pieto, M., additional, Vicente-Vicente, L., additional, Casanova, A.G., additional, López-Hernández, F.J., additional, and Morales, A.I., additional
- Published
- 2015
- Full Text
- View/download PDF
14. Subtoxic doses of calcineurin inhibitors induce predisposition to acute kidney injury
- Author
-
Prieto, M., primary, Casanova, A.G., additional, Hernández-Sánchez, M.T., additional, Vicente-Vicente, L., additional, Pescador, M., additional, López-Hernández, F.J., additional, and Morales, A.I., additional
- Published
- 2015
- Full Text
- View/download PDF
15. ESTUDIO DEL DAÑO RENAL SUBCLÍNICO ASOCIADO AL COTRATAMIENTO CON INHIBIDORES DEL PUNTO DE CONTROL INMUNITARIO Y CISPLATINO.
- Author
-
Tascón, J., Casanova, A. G., Vicente-Vicente, L., Pescador, M., Prieto, M., and Morales, A. I.
- Subjects
LIPOCALIN-2 ,UREA - Abstract
Los inhibidores del punto de control inmunitario (ICI), empleados como inmuterápicos, se han postulado como una nueva estrategia contra el cáncer, que incluso, en combinación con la quimioterapia han mejorado la eficacia del tratamiento, pero también ha aumentado el riesgo de sufrir efectos nefrotóxicos. La evidencia de daño renal, en ocasiones, no se detecta con el aumento de creatinina plasmática. Por ello, nuestra hipótesis es que el daño renal asociado a los ICI pudiera ser subclínico. El objetivo de este trabajo fue estudiar el daño renal asociado a una familia de ICI (anti-CTLA-4) en combinación con quimioterapia (cisplatino). Se utilizaron ratones C57BL/6 que fueron tratados con la terapia combinada de cisplatino (10 mg/kg, dosis única) y anti-CTLA-4 (10 o 15 mg/kg/día, durante 6 días) administrados mediante inyección intraperitoneal. Se incluyeron además grupos tratados con las monoterapias de los fármacos y un grupo control. Se recogieron muestras de orina y sangre el día basal del experimento y los días 3 y 6 (sacrificio). Se determinaron los biomarcadores urinarios de daño renal subclínico; albúmina, lipocalina asociada a la gelatinasa de neutrófilos (NGAL) y molécula de daño renal 1 (KIM-1) mediante ELISA. En las muestras de sangre se cuantificó creatinina y urea mediante técnicas colorimétricas. Los datos fueron analizados con el software estadístico SPSS. La creatinina y la urea se encontraron dentro del rango de normalidad por lo que no reflejaron con claridad la aparición de daño renal. Los biomarcadores de daño renal subclínico se elevaron significativamente en los grupos de terapia combinada con respecto a las monoterapias de fármacos y al grupo control. Este estudio sugiere que la combinación de anti-CTLA-4 con cisplatino presentaría un efecto potenciador del daño renal subclínico en comparación con los tratamientos administrados en monoterapia. [ABSTRACT FROM AUTHOR]
- Published
- 2022
16. AKI - experimental models
- Author
-
Lai, C.-F., primary, Lin, S.-L., additional, Chiang, W.-C., additional, Chen, Y.-M., additional, Kuo, M.-L., additional, Tsai, T.-J., additional, Hwang, H. S., additional, Choi, Y. A., additional, Park, K. C., additional, Yang, K. J., additional, Choi, H. S., additional, Kim, S. H., additional, Lee, S. J., additional, Chang, Y. K., additional, Kim, S. Y., additional, Yang, C. W., additional, Xiujuan, Z., additional, Yoshimura, R., additional, Matsuyama, M., additional, Chargui, J., additional, Touraine, J.-L., additional, Yoshimura, N., additional, Zulkarnaev, A. B., additional, Vasilenko, I. A., additional, Artemov, D. V., additional, Vatazin, A. V., additional, Park, S. K., additional, Kang, K. P., additional, Lee, S., additional, Kim, W., additional, Schneider, R., additional, Betz, B., additional, Moller-Ehrlich, K., additional, Wanner, C., additional, Sauvant, C., additional, Park, C. W., additional, Sohotnik, R., additional, Nativ, O., additional, Abbasi, A., additional, Awad, H., additional, Frajewicki, V., additional, Armaly, Z., additional, Heyman, S. N., additional, Abassi, Z., additional, Chen, P. Y., additional, Chen, B. L., additional, Yang, C. C., additional, Chiang, C. K., additional, Liu, S. H., additional, Abozahra, A. E., additional, Abd-Elkhabir, A. A., additional, Shokeir, A., additional, Hussein, A., additional, Awadalla, A., additional, Barakat, N., additional, Abdelaziz, A., additional, Yamaguchi, J., additional, Tanaka, T., additional, Eto, N., additional, Nangaku, M., additional, Quiros, Y., additional, Lopez-Hernandez, F. J., additional, Perez de Obanos, M. P., additional, Ruiz, J., additional, Lopez-Novoa, J. M., additional, Shin, H.-S., additional, Kim, M.-J., additional, Choi, Y.-J., additional, Ryu, E.-S., additional, Choi, H.-S., additional, Kang, D.-H., additional, Jankauskas, S. S., additional, Pevzner, I. B., additional, Zorova, L. D., additional, Babenko, V. A., additional, Morosanova, M. A., additional, Plotnikov, E. Y., additional, Zorov, D. B., additional, Huang, C.-Y., additional, Huang, T.-M., additional, Wu, V.-C., additional, Young, G.-H., additional, Chupyrkina, A. A., additional, Zorov, S. D., additional, Grande, J. P., additional, Hartono, S. P., additional, Knudsen, B. E., additional, Mederle, K., additional, Castrop, H., additional, Hocherl, K., additional, Iwakura, T., additional, Fujikura, T., additional, Ohashi, N., additional, Yasuda, H., additional, Fujigaki, Y., additional, Matsui, I., additional, Hamano, T., additional, Inoue, K., additional, Obi, Y., additional, Nakano, C., additional, Kusunoki, Y., additional, Tsubakihara, Y., additional, Rakugi, H., additional, Isaka, Y., additional, Shimomura, A., additional, Wallentin Guron, C., additional, Nguy, L., additional, Lundgren, J., additional, Grimberg, E., additional, Kashioulis, P., additional, Guron, G., additional, DiBona, G. F., additional, Nedergaard Mikkelsen, M., additional, Marcussen, N., additional, Saeed, A., additional, Edvardsson, K., additional, Lindberg, K., additional, Larsson, T., additional, Ito, K., additional, Nakashima, H., additional, Watanabe, M., additional, Abe, Y., additional, Ogahara, S., additional, Saito, T., additional, Albertoni, G., additional, Borges, F., additional, Schor, N., additional, Beresneva, O. N., additional, Parastayeva, M. M., additional, Kucher, A. G., additional, Ivanova, G. T., additional, Shved, N., additional, Rybakova, M. G., additional, Kayukov, I. G., additional, Smirnov, A. V., additional, Chen, J.-F., additional, Ni, H.-F., additional, Pan, M.-M., additional, Liu, H., additional, Xu, M., additional, Zhang, M.-H., additional, Liu, B.-C., additional, Kim, Y., additional, Choi, B. S., additional, Kim, Y. S., additional, Han, J. S., additional, Reis, L. A., additional, Christo, J. S., additional, Simoes, M. d. J., additional, Mulay, S. R., additional, Santhosh Kumar, V. R., additional, Kulkarni, O. P., additional, Darisipudi, M., additional, Lech, M., additional, Anders, H.-J., additional, Silachev, D. N., additional, Sola, A., additional, Jung, M., additional, Ventayol, M., additional, Mastora, C., additional, Buenestado, S., additional, Hotter, G., additional, Rong, S., additional, Shushakova, N., additional, Wensvoort, G., additional, Haller, H., additional, Gueler, F., additional, Morais, C., additional, Vesey, D. A., additional, Johnson, D. W., additional, Gobe, G. C., additional, Godo, M., additional, Kaucsar, T., additional, Revesz, C., additional, Hamar, P., additional, Cheng, Q., additional, Wen, J., additional, Ma, Q., additional, Zhao, J., additional, Castellano, G., additional, Stasi, A., additional, Di Palma, A. M., additional, Gigante, M., additional, Netti, G. S., additional, Curci, C., additional, Intini, A., additional, Divella, C., additional, Prattichizzo, C., additional, Fiaccadori, E., additional, Pertosa, G., additional, Grandaliano, G., additional, Gesualdo, L., additional, Wei, Q. W., additional, Jing, Q. Q., additional, Ying, N. J., additional, Dong, Q. Z., additional, Yong, G., additional, Pulkova, N. V., additional, Sukhikh, G. T., additional, Kim, S., additional, Lee, J., additional, Nam, N. J., additional, Na, K. Y., additional, Ma, S. K., additional, Joo, S. Y., additional, Kim, C. S., additional, Choi, J. S., additional, Bae, E. H., additional, Kim, S. W., additional, Cernaro, V., additional, Medici, M. A., additional, Donato, V., additional, Trimboli, D., additional, Lorenzano, G., additional, Santoro, D., additional, Montalto, G., additional, Buemi, M., additional, Longo, V., additional, Segreto, H. R. C., additional, Almeida, W., additional, Ramos, M. F., additional, Gomes, L., additional, Razvickas, C., additional, Gutberlet, M., additional, Meier, M., additional, Mengel, M., additional, Wacker, D., additional, Hueper, K., additional, Uzum, A., additional, Ersoy, R., additional, Cakalagaoglu, F., additional, Karaman, M., additional, Kolatan, E., additional, Sahin, O., additional, Yilmaz, O., additional, Cirit, M., additional, Inal, S., additional, Koc, E., additional, Okyay, G. U., additional, Pasaoglu, O., additional, Gonul, I., additional, Oyar, E., additional, Pasaoglu, H., additional, Guz, G., additional, Sabbatini, M., additional, Rossano, R., additional, Andreucci, M., additional, Pisani, A., additional, Riccio, E., additional, Choi, D. E., additional, Jeong, J. Y., additional, Kim, S. S., additional, Na, K.-R., additional, Lee, K. W., additional, Shin, Y. T., additional, Silva, A. F., additional, Teixeira, V. C., additional, Meszaros, K., additional, Koleganova-Gut, N., additional, Schaefer, F., additional, Ritz, E., additional, Walacides, D., additional, Ruskamp, N., additional, Schiffer, M., additional, Marom, O., additional, Haick, H., additional, Nakhoul, F., additional, Lv, L.-L., additional, Tang, R.-N., additional, Zhang, J.-D., additional, Ma, K.-L., additional, Chen, P.-S., additional, Ko, W.-J., additional, Misiara, G. P., additional, Coimbra, T. M., additional, Silva, G. E. B., additional, Costa, R. S., additional, Francescato, H. D. C., additional, Neto, M. M., additional, Dantas, M., additional, Olauson, H., additional, Amin, R., additional, Ponnusamy, A., additional, Goetz, R., additional, Mohammadi, M., additional, Canfield, A., additional, Kublickiene, K., additional, Rodriguez, J., additional, Reyes, E. P., additional, Cortes, P. P., additional, Fernandez, R., additional, Yoon, H. E., additional, Koh, E. S., additional, Chung, S., additional, Shin, S. J., additional, Pazzano, D., additional, Lupica, R., additional, Torre, F., additional, Costantino, G., additional, Prieto, M., additional, Gonzalez-Buitrago, J. M., additional, Lopez-Hernandez, F., additional, Morales, A. I., additional, Vicente-Vicente, L., additional, Ferreira, L., additional, Simoes, M. J., additional, Passos, C. d., additional, Schor, N. S., additional, Shimizu, M. H. M., additional, Canale, D., additional, de Braganca, A. C., additional, Andrade, L., additional, Luchi, W. M., additional, Seguro, A. C., additional, Goncalves, J., additional, Volpini, R. A., additional, Garrido, P., additional, Fernandes, J., additional, Ribeiro, S., additional, Vala, H., additional, Parada, B., additional, Alves, R., additional, Belo, L., additional, Costa, E., additional, Santos-Silva, A., additional, and Reis, F., additional
- Published
- 2013
- Full Text
- View/download PDF
17. AKI - Experimental
- Author
-
Kaynar, K., primary, Kaynar, K., additional, Ersoz, S., additional, Aliyazioglu, R., additional, Uzun, A., additional, Ulusoy, S., additional, Al, S., additional, Ozkan, G., additional, Cansiz, M., additional, Bertocchio, J.-P., additional, Lancon, J., additional, El Moghrabi, S., additional, Galmiche, G., additional, Duong Van Huyen, J.-P., additional, Rieu, P., additional, Jaisser, F., additional, Albertoni, G., additional, Andrade, S., additional, Barreto, J. A., additional, Borges, F., additional, Schor, N., additional, Ho, W.-Y., additional, Chen, S.-H., additional, Tseng, C.-J., additional, Bienholz, A., additional, Feldkamp, T., additional, Weinberg, J. M., additional, Suller Garcia, J., additional, Naves, M., additional, Aparecida Reis, L., additional, Simoes, M. d. J., additional, S Almeida, W., additional, Moreau Longo, V., additional, Segreto, H. R. C., additional, Ghoneim, A., additional, Elkholy, A., additional, Medhat Abbas, T., additional, El Hadeedy, M., additional, Elhusseini, F., additional, Elessawey, B., additional, Eltanaihy, E., additional, Lotfy, A., additional, Eldesoky, S., additional, Sheashaa, H., additional, Sobh, M., additional, Minning, D. M., additional, Warnock, D., additional, Mohamed, A. S., additional, Wirthlin, J. B., additional, Chintalacharuvu, S. R., additional, Boone, L., additional, Brenner, R. M., additional, Santina Christo, J., additional, Dos Santos Passos, C., additional, Rene de Alencar, D., additional, De Braganca, A. C., additional, Canale, D., additional, Goncalves, J. G., additional, Brandao, T. P. B., additional, Shimizu, M. H. M., additional, Volpini, R. A., additional, Seguro, A. C., additional, Andrade, L., additional, Lee, J.-W., additional, Kim, H. K., additional, Cho, W. Y., additional, Jo, S.-K., additional, Cho, E., additional, Hocherl, K., additional, Schmidt, C., additional, Mulay, S. R., additional, Kulkarni, O. P., additional, Rupanagudi, K. V., additional, Migliorini, A., additional, Liapis, H., additional, Anders, H.-J., additional, Pevzner, I., additional, Chupyrkina, A., additional, Plotnikov, E., additional, Zorov, D., additional, Lopez-Novoa, J.-M., additional, Eleno, N., additional, Perez-Barriocanal, F., additional, Arevalo, M., additional, Docherty, N., additional, Castellano, G., additional, Divella, C., additional, Loverre, A., additional, Stasi, A., additional, Curci, C., additional, Rossini, M., additional, Ditonno, P., additional, Battaglia, M., additional, Daha, M. R., additional, Van Kooten, C., additional, Gesualdo, L., additional, Schena, F. P., additional, Grandaliano, G., additional, Tsuda, H., additional, Kawada, N., additional, Iwatani, H., additional, Moriyama, T., additional, Takahara, S., additional, Rakugi, H., additional, Isaka, Y., additional, Schley, G., additional, Kalucka, J., additional, Klanke, B., additional, Jantsch, J., additional, Olbrich, S., additional, Baumgartl, J., additional, Amann, K., additional, Eckardt, K.-U., additional, Weidemann, A., additional, Dolgolikova, A., additional, Pilotovich, V., additional, Ivanchik, G., additional, Shved, I., additional, Banki, N. F., additional, Antal, Z., additional, Hosszu, A., additional, Koszegi, S., additional, Vannay, A., additional, Wagner, L., additional, Prokai, A., additional, Muller, V., additional, Szabo, A. J., additional, Fekete, A., additional, Farrag, S., additional, Abulasrar, S., additional, Salama, , M., additional, Amin, M., additional, Ali, A., additional, Rubera, I., additional, Duranton, C., additional, Cougnon, M., additional, Melis, N., additional, Tauc, M., additional, Jankauskas, S., additional, Morosanova, M., additional, Pulkina, N., additional, Zorova, L., additional, Shin, Y. T., additional, Kim, S. S., additional, Chang, Y. K., additional, Choi, D. E., additional, Na, K.-R., additional, Lee, K. W., additional, Choi, J.-Y., additional, Jin, D.-C., additional, Cha, J.-H., additional, Schneider, R., additional, Betz, B., additional, Meusel, M., additional, Held, C., additional, Wanner, C., additional, Gekle, M., additional, Sauvant, C., additional, Pisani, A., additional, Rossano, R., additional, Mancini, A., additional, Arfian, N., additional, Yagi, K., additional, Nakayama, K., additional, Ali, H., additional, Mayasari, D. S., additional, Purnomo, E., additional, Emoto, N., additional, Efrati, S., additional, Berman, S., additional, Abu Hamad, R., additional, Weissgarten, J., additional, Scherbaum, C. R., additional, Allam, R., additional, Lichtnekert, J., additional, Darisipudi, M. N., additional, Hagele, H., additional, Hohenstein, B., additional, Hugo, C., additional, Schaefer, L., additional, Corsi, C., additional, Ferramosca, E., additional, Grandi, E., additional, Pisoni, L., additional, Rivolta, I., additional, Dalpozzo, B., additional, Hoxha, E., additional, Severi, S., additional, Santoro, A., additional, Laurent, M., additional, Cedric, R., additional, Dominique, C., additional, Sophie, V., additional, Nochy, D., additional, Loic, G., additional, Patrice, C., additional, Chantal, J., additional, Marie-Christine, V., additional, Alexandre, H., additional, Eric, R., additional, Cantaluppi, V., additional, Medica, D., additional, Quercia, A. D., additional, Figliolini, F., additional, Dellepiane, S., additional, Randone, O., additional, Segoloni, G. P., additional, Camussi, G., additional, Ahn, B.-H., additional, Kim, S. H., additional, Yasue Saito Miyagi, M., additional, Camara, N., additional, Cerqueira Leite Seelaender, M., additional, Maceratesi Enjiu, L., additional, Estler Rocha Guilherme, P., additional, Pisciottano, M., additional, Hiyane, M., additional, Yuri Hayashida, C., additional, De Andrade Oliveira, V., additional, Olsen Saraiva Camara, N., additional, Tami Amano, M., additional, Sancho-Martinez, S. M., additional, Sanchez-Juanes, F., additional, Vicente, L., additional, Gonzalez-Buitrago, J. M., additional, Morales, A. I., additional, Lopez-Novoa, J. M., additional, Lopez-Hernandez, F. J., additional, Chen, J.-S., additional, Chang, L.-C., additional, Chen, C.-C., additional, Park, M. Y., additional, Choi, S. J., additional, Kim, J. G., additional, Hwang, S. D., additional, Vicente-Vicente, L., additional, Ferreira, L., additional, Prieto, M., additional, Garcia-Sanchez, O., additional, Sevilla, M. A., additional, Lopez-Novoa, F. J., additional, Christoph, K., additional, Kuper, C., additional, Maria-Luisa, F., additional, Franz-Xaver, B., additional, Neuhofer, W., additional, Vervaet, B., additional, Le Clef, N., additional, Verhulst, A., additional, D'haese, P., additional, Tanaka, T., additional, Yamaguchi, J., additional, Eto, N., additional, Kojima, I., additional, Fujita, T., additional, Nangaku, M., additional, Wystrychowski, A., additional, Wystrychowski, G., additional, Obuchowicz, E., additional, Grzeszczak, W., additional, Wiecek, A., additional, Esposito, C., additional, Torreggiani, M., additional, Castoldi, F., additional, Migotto, C., additional, Serpieri, N., additional, Grosjean, F., additional, Manini, A., additional, Pertile, E., additional, and Dal Canton, A., additional
- Published
- 2012
- Full Text
- View/download PDF
18. Acute kidney injury - Experimental models
- Author
-
Nagasaki, Y., primary, Yoshitomi, T., additional, Hirayama, A., additional, Schock-Kusch, D., additional, Xie, Q., additional, Shulhevich, Y., additional, Hesser, J., additional, Stsepankou, S., additional, Koenig, S., additional, Heinrich, R., additional, Pill, J., additional, Gretz, N., additional, Efrati, S., additional, Berman, S., additional, Abu-Hamad, R., additional, Siman-Tov, Y., additional, Weissgarten, J., additional, Kimura, T., additional, Takabatake, Y., additional, Takahashi, A., additional, Kaimori, J.-y., additional, Matsui, I., additional, Namba, T., additional, Kitamura, H., additional, Niimura, F., additional, Matsusaka, T., additional, Rakugi, H., additional, Isaka, Y., additional, Ito, K., additional, Watanabe, M., additional, Nakashima, H., additional, Abe, Y., additional, Ifuku, M., additional, Nishimura, S., additional, Saito, T., additional, Mulay, S. R., additional, Thomasova, D., additional, Ryu, M., additional, Anders, H.-J., additional, Nakayama, Y., additional, Ueda, S., additional, Yamagishi, S.-i., additional, Ando, R., additional, Kaida, Y., additional, Iwatani, R., additional, Fujimi, A., additional, Fukami, K., additional, Okuda, S., additional, Shin, Y. T., additional, Jeong, J. Y., additional, Jang, W. I., additional, Chung, S., additional, Choi, D. E., additional, Na, K. R., additional, Lee, K. W., additional, Mugitani, N., additional, Shimizu, Y., additional, Satake, K., additional, Suzuki, Y., additional, Horikoshi, S., additional, Tomino, Y., additional, Schneider, R., additional, Meusel, M., additional, Betz, B., additional, Wanner, C., additional, Koepsell, H., additional, Sauvant, C., additional, Dursun, B., additional, Abban, G., additional, Kucukatay, V., additional, Tufan, L., additional, Dodurga, Y., additional, Guclu, A., additional, Gok, D., additional, Vicente-Vicente, L., additional, Sanchez-Gonzalez, P. D., additional, Prieto, M., additional, Lopez-Novoa, J. M., additional, Lopez-Hernandez, F. J., additional, Morales, A. I., additional, Torres, A., additional, Dnyanmote, A., additional, Wu, W., additional, Nigam, S., additional, Wystrychowski, A., additional, Wystrychowski, W., additional, Kolodziejczyk, A., additional, Obuchowicz, E., additional, Wiecek, A., additional, Reis, L. A., additional, Borges, F. T., additional, Simoes, M. d. J., additional, Schor, N., additional, Mesnard, L., additional, Rafat, C., additional, Vandermeersch, S., additional, Nochy, D., additional, Garcon, L., additional, Callard, P., additional, Jouanneau, C., additional, Verpont, M.-C., additional, Hertig, A., additional, Rondeau, E., additional, Grosjean, F., additional, Torreggiani, M., additional, Esposito, V., additional, Mangione, F., additional, Serpieri, N., additional, Villa, L., additional, Sileno, G., additional, Marchi, G., additional, Fasoli, G., additional, Esposito, C., additional, Dal Canton, A., additional, Sancho-Martinez, S., additional, Striker, G., additional, Vlassara, H., additional, Zheng, F., additional, Park, D. J., additional, Kim, J. H., additional, Jung, M. H., additional, Seo, J. W., additional, Kim, H.-j., additional, Chang, S.-H., additional, Han, B.-G., additional, Yang, J.-W., additional, Yu, J.-M., additional, Choi, S.-O., additional, Christo, J. S., additional, Rusai, K., additional, Prokai, A., additional, Szebeni, B., additional, Meszaros, K., additional, Fekete, A., additional, Treszl, A., additional, Vannay, A., additional, Muller, V., additional, Reusz, G., additional, Heemann, U., additional, Tulassay, T., additional, Lutz, J., additional, Szabo, A. J., additional, Ranghino, A., additional, Bruno, S., additional, Grange, C., additional, Dolla, C., additional, Cantaluppi, V., additional, Biancone, L., additional, Tetta, C., additional, Segoloni, G. P., additional, Camussi, G., additional, Pinto, V., additional, Teixeira, V., additional, Almeida, W., additional, Fujikura, T., additional, Sun, Y., additional, Iwakura, T., additional, Yasuda, H., additional, Fujigaki, Y., additional, Simone, S., additional, Rascio, F., additional, Loverre, A., additional, Cosola, C., additional, Cariello, M., additional, Castellano, G., additional, Ditonno, P., additional, Schena, F. P., additional, Gesualdo, L., additional, Grandaliano, G., additional, Pertosa, G., additional, Choi, J.-Y., additional, Kim, J., additional, Jin, D.-C., additional, Cha, J.-H., additional, Kaynar, K., additional, Aliyazicioglu, R., additional, Ersoz, S., additional, Ulusoy, S., additional, Al, S., additional, Ozkan, G., additional, Cansiz, M., additional, Fuchs, T. C., additional, Emde, B., additional, Czasch, S., additional, von Landenberg, F., additional, Hewitt, P., additional, Abu-Salah, N., additional, Bishara, B., additional, Awad, H., additional, Ghrayeb, N., additional, Assady, S., additional, Armaly, Z., additional, Better, O., additional, and Abassi, Z., additional
- Published
- 2011
- Full Text
- View/download PDF
19. An Integrative Overview on the Mechanisms Underlying the Renal Tubular Cytotoxicity of Gentamicin
- Author
-
Quiros, Y., primary, Vicente-Vicente, L., additional, Morales, A. I., additional, Lopez-Novoa, J. M., additional, and Lopez-Hernandez, F. J., additional
- Published
- 2010
- Full Text
- View/download PDF
20. Renoprotective effects of quercetin on cisplatin-induced nephrotoxicity. Role of TNF-alpha, NF-kappaB and iNOS
- Author
-
Sánchez-González, P., primary, López-Hernández, F.J., additional, Prierto, M., additional, Vicente-Vicente, L., additional, López-Novoa, J.M., additional, and Morales, A.I., additional
- Published
- 2010
- Full Text
- View/download PDF
21. LOS BIOMARCADORES URINARIOS IGFBP7 E IGFBP7 X TIMP2 IDENTIFICAN A LOS PACIENTES EN RIESGO DE SUFRIR NEFROTOXICIDAD POR MEDIOS DE CONTRASTE.
- Author
-
Casanova, A. G., García-Quintero, P., Hernández-Vicente, R., Tascón, J., Prieto, M., Pescador, M., López-Hernández, F. J., Morales, A. I., and Vicente-Vicente, L.
- Subjects
BIOMARKERS ,NEPHROTOXICOLOGY ,EXCRETION ,PROTEINS - Abstract
Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
22. PAPEL DE LA INFLAMACIÓN EN LA NEFROTOXICIDAD ASOCIADA AL TRATAMIENTO DE INMUNOTERAPIA Y QUIMIOTERAPIA.
- Author
-
Prieto, M., Tascón, J., Arnaiz, L., Casanova, A. G., Vicente-Vicente, L., Pescador, M., and Morales, A. I.
- Subjects
IMMUNE checkpoint inhibitors ,COMBINATION drug therapy ,KIDNEY physiology ,IMMUNOTHERAPY ,NEPHROTOXICOLOGY - Abstract
Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
23. ESTUDIO HISTOLÓGICO DE LA NEFROTOXICIDAD ASOCIADA A LOS INHIBIDORES DEL PUNTO DE CONTROL INMUNITARIO COMBINADOS CON QUIMIOTERAPIA EN UN MODELO MURINO.
- Author
-
Tascón, J., Casanova, A. G., Vicente-Vicente, L., Pescador, M., Morales, A. I., and Prieto, M.
- Subjects
GAS chromatography/Mass spectrometry (GC-MS) ,IMMUNE checkpoint inhibitors ,EXTRACTION techniques ,ENVIRONMENTAL risk ,NERVOUS system - Abstract
Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
24. P-TE/08- INFLUENCIA DE LA VÍA DE ADMINISTRACIÓN EN EL EFECTO NEFROPROTECTOR DE LA QUERCETINA. POSIBLE PAPEL DE LOS METABOLITOS METILADOS.
- Author
-
Casanova, A., González-Parámas, A. M., Muñoz-Reyes, D., Vicente-Vicente, L., Hernández-Sánchez, M. T., López-Hernández, F., Santos-Buelga, C., Morales, A. I., and Prieto, M.
- Abstract
Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
25. P-ET/06- LA VISIÓN PROFESIONAL DE TEMAS TOXICOLÓGICOS EN EL AULA, UNA ACTIVIDAD DOCENTE QUE ESTIMULA EL APRENDIZAJE Y EL ESPÍRITU CRÍTICO.
- Author
-
Vicente-Vicente, L., Prieto, M., Pescador, M., Casanova, A. G., Hernández-Sánchez, M. T., and Morales, A. I.
- Abstract
Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
26. APRENDIENDO TOXICOLOGÍA A TRAVÉS DE LA PLATAFORMA MIRIADAX. UNA PRIMERA EXPERIENCIA CON EL PROYECTO TOX-OER.
- Author
-
Vicente-Vicente, L., M., Prieto, M., Pescador, A. G., Casanova, Hernández-Sánchez, M. T., F. E., Almaraz-Menéndez, and A. I., Morales
- Published
- 2017
27. P-TC/15- DETECCIÓN DEL RIESGO DE NEFROTOXICIDAD EN INDIVIDUOS FUMADORES.
- Author
-
Prieto, M., Hernández-Sánchez, M. T., Sanz-Parras, F. J., Vicente-Vicente, L., Casanova, A., Tascón, J., Pescador, M., and Morales, A. I.
- Abstract
Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
28. P-TC/13- CORRELACIÓN ENTRE EL DESARROLLO DE DAÑO RENAL TEMPRANO Y EL CONSUMO DE TABACO.
- Author
-
Casanova, A. G., Prieto, M., Vicente-Vicente, L., Hernández-Sánchez, M. T., Sanz-Parras, F. J., Martínez-Carretero, P., Pescador, M., and Morales, A. I.
- Abstract
Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
29. P-TC/12-EXPOSICIÓN A PESTICIDAS Y RIESGO DE DAÑO RENAL TEMPRANO.
- Author
-
Casanova, A. G., van Herckenrode-Sánchez, A., Martín-Reina, J., Hernández-Sánchez, M. T., Vicente-Vicente, L., Prieto, M., Pescador, M., Bautista, J. D., I., Moreno, and Morales, A..I.
- Abstract
Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
30. P-ET/08- MOOC SOBRE EFECTO DE LOS TÓXICOS EN EL SISTEMA NERVIOSO, UNA OPORTUNIDAD PARA ADQUIRIR CONOCIMIENTOS TOXICOLÓGICOS.
- Author
-
Vicente-Vicente, L., Prieto, M., Pescador, M., Casanova, A. G., Hernández-Sánchez, M. T., and Morales, A. I.
- Abstract
Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
31. O-TC/03- PREDICCIÓN DE LA NEFROTOXICIDAD DE LOS MEDIOS DE CONTRASTE MEDIANTE EL USO DE NUEVOS MARCADORES.
- Author
-
Hernández-Sánchez, M. T., Vicente-Vicente, L., Prieto, M., Cruz- González, I., Casanova, A. G., Pliego-Morante, R., López-Hernández, F. J., and Morales, A. I.
- Abstract
Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
32. O-TE/01- EL TEST DE ESTRÉS DE LA FUROSEMIDA COMO HERRAMIENTA DIAGNÓSTICA DE LA NEFROTOXICIDAD ASOCIADA A DAÑO TUBULAR.
- Author
-
Hernández-Sánchez, M. T., Casanova, A. G., Caballero, M. T., Eleno, N., Fuentes-Calvo, I., Vicente-Vicente, L., Prieto, M., Martínez-Salgado, C., López-Hernández, F. J., and Morales, A. I.
- Abstract
Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
33. UTILIDAD DE LA DETERMINACIÓN DE COTININA URINARIA FRENTE AL TEST DE FAGERSTRÖM EN LA EVALUACIÓN DEL CONSUMO DE TABACO.
- Author
-
Hernández-Sánchez, M. T., Vicente-Vicente, L., Sanz-Parras, F. J., Casanova, A. G., Pescador, M., Prieto, M., and Morales, A. I.
- Published
- 2017
34. ANÁLISIS DE LA NEFROTOXICIDAD EN PACIENTES TRASPLANTADOS DE RIÑÓN MEDIANTE BIOMARCADORES DE DAÑO RENAL TEMPRANO.
- Author
-
Hernández-Sánchez, M. T., Tabernero-Fernández, G., Pescador, M., A. G., Casanova, Vicente-Vicente, L., A. I., Morales, and M., Prieto
- Published
- 2017
35. LA PREDISPOSICIÓN AL FRACASO RENAL AGUDO INDUCIDO POR CISPLATINO PUEDE SER IDENTIFICADA MEDIANTE LAS PROTEÍNAS FUMARILACETOACETASA, TRANSFERRINA Y ALBÚMINA.
- Author
-
A. G., Casanova, Vicente-Vicente, L., Hernández-Sánchez, M. T., M. I., Rihuete, L. M., Ramis, del Barco, E., Gómez-Bernal A, A., M., Prieto, Pescador, M., López-Hernández, F. J., and A. I., Morales
- Published
- 2017
36. BÚSQUEDA DE FUTUROS INVESTIGADORES ENTRE LOS ESTUDIANTES DE PREGRADO: PROGRAMA INICIO A LA INVESTIGACIÓN.
- Author
-
A. G., Casanova, Hernández-Sánchez, M. T., Vicente-Vicente, L., M., Prieto, M., Pescador, and A. I., Morales
- Published
- 2017
37. BIOMARCADORES DE NEFROTOXICIDAD CAPACES DE IDENTIFICAR PACIENTES ONCOLÓGICOS EN RIESGO DE DESARROLLAR DAÑO RENAL.
- Author
-
A. G., Casanova, Vicente-Vicente, L., Hernández-Sánchez, M. T., Rihuete, M. I., L. M., Ramis, F., Alioto, Duarte, J., del Barco, E., Gómez-Bernal, A., M., Prieto, M., Pescador, F. J., López- Hernández, and A. I., Morales
- Published
- 2017
38. Urinary GM2AP coincides with renal cortical damage and grades cisplatin nephrotoxicity severity in rats.
- Author
-
Blanco-Gozalo V, Quiros Y, Vicente-Vicente L, Casanova AG, Sancho-Martínez SM, and López-Hernández FJ
- Subjects
- Animals, Male, Rats, Gentamicins toxicity, Rats, Sprague-Dawley, Lipocalin-2 urine, Severity of Illness Index, Cisplatin toxicity, Biomarkers urine, Antineoplastic Agents toxicity, Kidney Cortex drug effects, Kidney Cortex pathology, Kidney Cortex metabolism, G(M2) Activator Protein, Acute Kidney Injury chemically induced, Acute Kidney Injury pathology, Acute Kidney Injury urine
- Abstract
Nephrotoxicity, including electrolytic disorders and acute kidney injury (AKI), limits the clinical dosage and utility of platinated antineoplastics such as cisplatin. Cisplatin nephrotoxicity embodies a tubulopathy involving the medullary S2 and S3 segments of the proximal and the distal tubules. Higher dosage extends damage over the cortical S1 segment and intensifies overall injury. However, the standard diagnosis based on plasma creatinine as well as novel injury biomarkers lacks enough pathophysiological specificity. Further granularity in the detection of renal injury would help understand the implications of individual damage patterns needed for personalized patient handling. In this article, we studied the association of urinary ganglioside GM2 activator protein (GM2AP) with the patterns of tubular damage produced by 5 and 10 mg/kg cisplatin in rats. Our results show that GM2AP appears in the urine only following damage to the cortical segment of the proximal tubule. The information provided by GM2AP is not redundant with but distinct and complementary to that provided by urinary neutrophil gelatinase-associated lipocalin (NGAL). Similarly, treatment with 150 mg/kg/day gentamicin damages the renal cortex and increases GM2AP urinary excretion; whereas renal ischemia, which does not affect the cortex, has no effect on GM2AP. Because of the key role of the cortical proximal tubule in renal function, we contend GM2AP as a potential diagnostic biomarker to stratify AKI patients according to the underlying damage and follow their evolution and prognosis. Prospectively, urinary GM2AP may help grade the severity of platinated antineoplastic nephrotoxicity by forming part of a non-invasive liquid biopsy., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Competing interests The authors declare no competing interests., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
39. Effect of uric acid reduction on chronic kidney disease. Systematic review and meta-analysis.
- Author
-
Casanova AG, Morales AI, Vicente-Vicente L, and López-Hernández FJ
- Abstract
Accumulating evidence suggests that hyperuricemia is a pathological factor in the development and progression of chronic kidney disease. However, the potential benefit afforded by the control of uric acid (UA) is controversial. Individual studies show discrepant results, and most existing meta-analysis, especially those including the larger number of studies, lack a placebo or control group as they aim to compare efficacy between drugs. On these grounds, we performed a me-ta-analysis restricted to studies including the action of any anti-gout therapies referenced to a control or placebo arm. This approach allows for a clearer association between UA reduction and renal effect. Of the twenty-nine papers included, most used allopurinol and febuxostat and, therefore, solid conclusions could only be obtained for these drugs. Both were very effective in reducing UA, but only allopurinol was able to significantly improve glomerular filtration rate (GFR), although not in a dose-dependent manner. These results raised doubts as to whether it is the hypouricemic effect of anti-gout drugs, or a pleiotropic effect, what provides protection of kidney function. Accordingly, in a correlation study that we next performed between UA reduction and GFR improvement, no association was found, which suggests that additional mechanisms may be involved. Of note, most trials show large inter-individual response variability, probably because they included patients with heterogeneous phenotypes and pathological characteristics, including different stages of CKD and comorbidities. This highlights the need to sub classify the effect of UA-lowering therapies according to the pathological scenario, in order to identify those CKD patients that may benefit most from them. Systematic Review Registration: CRD42022306646 https://www.crd.york.ac.uk/prospero/., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Casanova, Morales, Vicente-Vicente and López-Hernández.)
- Published
- 2024
- Full Text
- View/download PDF
40. New Challenges in the Diagnosis of Kidney Damage Due to Immune Checkpoint Inhibitors Therapy: An Observational Clinical Study.
- Author
-
Vicente-Vicente L, Casanova AG, Tascón J, Prieto M, and Morales AI
- Abstract
In recent years, immunotherapy has been postulated as one of the most effective strategies in the fight against cancer. The greatest success in this field has been achieved with the inhibition of molecules involved in slowing down the adaptive immune response by immune checkpoint inhibitors (ICIs). Despite its efficacy, ICI treatment has side effects. Regarding kidney damage, it is estimated that 4.9% of patients treated with ICIs develop renal injury. Furthermore, cancer patients who develop renal dysfunction have a worse prognosis. Current diagnostics are insufficient to predict the underlying renal injury and to identify the type of damage. Our hypothesis is that the renal injury could be subclinical, so the possibility of using new urinary biomarkers could be a useful diagnostic tool that would allow these patients to be managed in a preventive (risk biomarkers) and early (early biomarkers) way and even to clarify whether the renal damage is due to this therapy or to other factors (differential diagnostic biomarkers). A prospective study to validate risk and early and differential biomarkers in patients treated with ICIs is proposed to test this hypothesis. The results derived from this study will improve the clinical practice of cancer treatment with ICIs and therefore the life expectancy and quality of life of patients. Trial Registration: ClinicalTrials.gov, NCT04902846., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2023
- Full Text
- View/download PDF
41. Diagnosis of Cardiac Surgery-Associated Acute Kidney Injury: State of the Art and Perspectives.
- Author
-
Casanova AG, Sancho-Martínez SM, Vicente-Vicente L, Ruiz Bueno P, Jorge-Monjas P, Tamayo E, Morales AI, and López-Hernández FJ
- Abstract
Diagnosis of cardiac surgery-associated acute kidney injury (CSA-AKI), a syndrome of sudden renal dysfunction occurring in the immediate post-operative period, is still sub-optimal. Standard CSA-AKI diagnosis is performed according to the international criteria for AKI diagnosis, afflicted with insufficient sensitivity, specificity, and prognostic capacity. In this article, we describe the limitations of current diagnostic procedures and of the so-called injury biomarkers and analyze new strategies under development for a conceptually enhanced diagnosis of CSA-AKI. Specifically, early pathophysiological diagnosis and patient stratification based on the underlying mechanisms of disease are presented as ongoing developments. This new approach should be underpinned by process-specific biomarkers including, but not limited to, glomerular filtration rate (GFR) to other functions of renal excretion causing GFR-independent hydro-electrolytic and acid-based disorders. In addition, biomarker-based strategies for the assessment of AKI evolution and prognosis are also discussed. Finally, special focus is devoted to the novel concept of pre-emptive diagnosis of acquired risk of AKI, a premorbid condition of renal frailty providing interesting prophylactic opportunities to prevent disease through diagnosis-guided personalized patient handling. Indeed, a new strategy of risk assessment complementing the traditional scores based on the computing of risk factors is advanced. The new strategy pinpoints the assessment of the status of the primary mechanisms of renal function regulation on which the impact of risk factors converges, namely renal hemodynamics and tubular competence, to generate a composite and personalized estimation of individual risk.
- Published
- 2022
- Full Text
- View/download PDF
42. Early Diagnosis of Kidney Damage Associated with Tobacco Use: Preventive Application.
- Author
-
Tascón J, Prieto M, Casanova AG, Sanz FJ, Hernández Mezquita MA, Barrueco Ferrero M, Gomez-Marcos MA, Garcia-Ortiz L, Vicente-Vicente L, Morales AI, and On Behalf Of Biotab Team
- Abstract
Although long-term smoking has been associated with chronic kidney disease, its effect on kidney function in early stages has not been clarified. Therefore, the proposed objectives were: (1) to identify subclinical kidney damage in smokers, through a panel of biomarkers; (2) to evaluate the progression of subclinical kidney damage after two years of consumption in these patients; and (3) study whether quitting smoking reduces kidney damage. A prospective study was carried out (patients recruited from a primary care centre and a clinical smoking unit). Kidney function was assessed using a panel of biomarkers and compared between smokers and non-smokers, taking into account potential risk factors for kidney damage. These results show, for the first time in the literature, the relationship between smoking and early (subclinical) kidney damage and provide a panel of biomarkers capable of detecting this condition (Neutrophil gelatinase-associated lipocalin, Kidney injury molecule-1, N-acetyl-beta-D-glucosaminidase, transferrin, and ganglioside-activating protein GM2). This study also indicates that subclinical damage is maintained when use continues, but can be reversed if patients stop smoking. The use of these biomarkers as diagnostic tools can be a preventive measure in the development of chronic kidney disease associated with smoking and in the prevention of acute events associated with potentially nephrotoxic pharmacological treatment in smokers. Trial registration number: NCT03850756.
- Published
- 2022
- Full Text
- View/download PDF
43. Albuminuria Pre-Emptively Identifies Cardiac Patients at Risk of Contrast-Induced Nephropathy.
- Author
-
Vicente-Vicente L, Casanova AG, Hernández-Sánchez MT, Prieto M, Martínez-Salgado C, López-Hernández FJ, Cruz-González I, and Morales AI
- Abstract
Contrast-induced nephropathy (CIN) is a complication associated with the administration of contrast media (CM). The CIN diagnosis is based on creatinine, a biomarker late and insensitive. The objective proposed was to evaluate the ability of novel biomarkers to detect patients susceptible to suffering CIN before CM administration. The study was carried out with patients undergoing cardiac catheterization involving CM. Patients were divided into two groups: (1) CIN, patients who developed this pathology; (2) control, patients who did not suffer CIN. Prior to the administration of CM, urine samples were collected to measure proteinuria, N -acetyl-β-d-glucosaminidase, neutrophil gelatinase-associated lipocalin and kidney injury molecule-1, albumin, transferrin, t-gelsolin and GM2 ganglioside activator protein (GM2AP). The risk factors advanced age, low body mass index and low estimated glomerular filtration rate; and the urinary biomarkers albumin, transferrin and GM2AP showed significant predictive capacity. Of all of them, albuminuria demonstrated the highest diagnostic power. When a cutoff point was established for albuminuria at values still considered subclinical (10-30 µg/mg Cr
u ), it was found that there was a high incidence of CIN (40-75%). Therefore, albuminuria could be applied as a new diagnostic tool to prevent and predict CIN with P4 medicine criteria, independently of risk factors and comorbidities.- Published
- 2021
- Full Text
- View/download PDF
44. Are Antioxidants Useful in Preventing the Progression of Chronic Kidney Disease?
- Author
-
Casanova AG, López-Hernández FJ, Vicente-Vicente L, and Morales AI
- Abstract
Chronic kidney disease (CKD) is a progressive impairment of renal function for more than three months that affects 15% of the adult population. Because oxidative stress is involved in its pathogenesis, antioxidants are under study for the prophylaxis of CKD progression. The objective of this work was to meta-analyze the efficacy of antioxidant therapy in CKD patients and to identify the most effective candidate antioxidants. Our meta-analysis showed that, despite being quite heterogeneous, overall antioxidant therapy apparently reduced CKD progression. Pentoxifylline and bardoxolone methyl demonstrated a robust and statistically significant protection, while other products showed a favorable but non-significant tendency, due to a high interindividual variability. Off-target (i.e., antioxidant-independent) effects, such as body weight reduction and heart failure-associated blood dilution, might totally or partially explain the protection provided by effective antioxidants. This potential pleiotropy introduces uncertainty on the role of oxidative stress in CKD progression and on antioxidant therapy in its prevention, which needs to be further investigated. Independently, identification of factors determining the nephroprotective effect of each candidate on each patient is thus necessary for a prospectively personalized antioxidant therapy. Finally, pentoxifylline should be further explored for the prophylaxis of CKD progression.
- Published
- 2021
- Full Text
- View/download PDF
45. Regression Modeling of the Antioxidant-to-Nephroprotective Relation Shows the Pivotal Role of Oxidative Stress in Cisplatin Nephrotoxicity.
- Author
-
Casanova AG, Harvat M, Vicente-Vicente L, Pellicer-Valero ÓJ, Morales AI, López-Hernández FJ, and Martín-Guerrero JD
- Abstract
The clinical utility of the chemotherapeutic drug cisplatin is significantly limited by its nephrotoxicity, which is characterized by electrolytic disorders, glomerular filtration rate decline, and azotemia. These alterations are consequences of a primary tubulopathy causing injury to proximal and distal epithelial cells, and thus tubular dysfunction. Oxidative stress plays a role in cisplatin nephrotoxicity and cytotoxicity, but its relative contribution to overall toxicity remains unknown. We studied the relation between the degree of oxidative reduction (provided by antioxidant treatment) and the extent of nephrotoxicity amelioration (i.e., nephroprotection) by means of a regression analysis of studies in animal models. Our results indicate that a linear relation exists between these two parameters, and that this relation very nearly crosses the value of maximal nephroprotection at maximal antioxidant effect, suggesting that oxidative stress seems to be a pivotal and mandatory mechanism of cisplatin nephrotoxicity, and, hence, an interesting, rationale-based target for clinical use. Our model also serves to identify antioxidants with enhanced effectiveness by comparing their actual nephroprotective power with that predicted by their antioxidant effect. Among those, this study identified nanoceria, erythropoietin, and maltol as highly effective candidates affording more nephroprotection than expected from their antioxidant effect for prospective clinical development.
- Published
- 2021
- Full Text
- View/download PDF
46. Pathophysiological mechanisms underlying a rat model of triple whammy acute kidney injury.
- Author
-
Prieto-García L, Vicente-Vicente L, Blanco-Gozalo V, Hidalgo-Thomas O, García-Macías MC, Kurtz A, Layton AT, Sanz AB, Morales AI, Martínez-Salgado C, Pericacho M, Sancho-Martínez SM, and López-Hernández FJ
- Subjects
- Animals, Blood Pressure drug effects, Drug Therapy, Combination adverse effects, Furosemide adverse effects, Ibuprofen adverse effects, Indoles adverse effects, Male, Rats, Wistar, Renal Circulation drug effects, Acute Kidney Injury chemically induced, Angiotensin-Converting Enzyme Inhibitors adverse effects, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Disease Models, Animal, Diuretics adverse effects
- Abstract
Simultaneous administration of certain antihypertensive (renin-angiotensin system inhibitors and diuretics) and nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a renal toxicity syndrome known as "triple whammy" acute kidney injury (TW-AKI), yet poorly characterized at the pathophysiological level, as no specific experimental model exists on which to conduct preclinical research. Herein, we generated and characterized a rat model of TW-AKI (0.7 mg/kg/day trandolapril +400 mg/kg/day ibuprofen +20 mg/kg/day furosemide). Double treatments involving the NSAID caused a subclinical acute kidney injury, as they reduced glomerular filtration rate to a significant but not sufficient extent to increase Cr
pl concentration. Only the triple treatment generated an overt AKI with increased Crpl provided that animals were under partial water ingestion restriction. Histological examination revealed no evidence of tissue renal injury, and no proteinuria or makers of renal damage were detected in the urine. These findings, along with a normal fractional excretion of sodium and glucose, indicated that these drug combinations produce a prerenal type of AKI. In fact, blood pressure and renal blood flow were also reduced (most markedly following the triple combination), although renal dysfunction was more pronounced than expected for the corresponding pressure drop, supporting a key pathological role of the interference with renal autoregulation mechanisms. In summary, prerenal TW-AKI only occurs when volemia is challenged (i.e., by furosemide in partially water-deprived animals) under the effects of renin-angiotensin system inhibitors and NSAIDs. This model will facilitate further pathophysiological knowledge for a better diagnosis and clinical handling of this syndrome.- Published
- 2020
- Full Text
- View/download PDF
47. A meta-analysis of preclinical studies using antioxidants for the prevention of cisplatin nephrotoxicity: implications for clinical application.
- Author
-
Casanova AG, Hernández-Sánchez MT, Martínez-Salgado C, Morales AI, Vicente-Vicente L, and López-Hernández FJ
- Subjects
- Animals, Antioxidants therapeutic use, Drug-Related Side Effects and Adverse Reactions, Humans, Kidney drug effects, Kidney Tubules, Antioxidants pharmacology, Cisplatin toxicity
- Abstract
Cisplatin is an effective chemotherapeutic drug whose clinical use and efficacy are limited by its nephrotoxicity, which affects mainly the renal tubules and vasculature. It accumulates in proximal and distal epithelial tubule cells and causes oxidative stress-mediated cell death and malfunction. Consequently, many antioxidants have been tested for their capacity to prevent cisplatin nephrotoxicity. In this study, we made a systematic review of the literature and meta-analyzed 152 articles, which tested the nephroprotective effect of isolated compounds or mixtures of natural origin on cisplatin nephrotoxicity in preclinical models. This meta-analysis identified the most effective candidates and examined the efficacy obtained by antioxidants administered by the oral and intraperitoneal routes. By comparing with a recent, similar meta-analysis performed on clinical studies, this article identifies a disconnection between preclinical and clinical research, and contextualizes, discusses, and integrates the existing preclinical information toward the optimized selection of candidates to be further explored (clinical level). Despite proved efficacy, this article discusses the barriers limiting the clinical development of natural mixtures, such as those in extracts from Calendula officinalis flowers and Heliotropium eichwaldii roots. On the contrary, isolated compounds are more straightforward candidates, among which arjunolic acid and quercetin stand out in this meta-analysis.
- Published
- 2020
- Full Text
- View/download PDF
48. Designing new diagnostic systems for the early detection of tobacco-associated chronic renal damage in patients of a primary care centre in Salamanca, Spain: an observational, prospective study protocol.
- Author
-
Prieto M, Vicente-Vicente L, Casanova AG, Hernández-Sánchez MT, Gomez-Marcos MA, Garcia-Ortiz L, and Morales AI
- Subjects
- Albuminuria blood, Biomarkers, Cross-Sectional Studies, G(M2) Activator Protein blood, Gelsolin blood, Humans, Kidney Function Tests, Longitudinal Studies, Primary Health Care, Prospective Studies, Research Design, Risk Factors, Severity of Illness Index, Spain, Transferrin analysis, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic etiology, Tobacco Use adverse effects
- Abstract
Introduction: Tobacco causes kidney damage that can progress to chronic kidney disease. However, the diagnostic parameters used in clinics are not effective in identifying smokers at risk. Our first objective is to more effectively detect subclinical renal damage in smokers. In addition, we hypothesise that tobacco consumption can predispose smokers to renal damage on exposure to other potentially nephrotoxic events (drugs, diagnostic procedures and so on). We will test this hypothesis in our second objective by investigating whether certain predisposition markers (GM2 ganglioside activator protein (GM2AP), transferrin and t-gelsolin) are able to detect smokers who are predisposed to kidney damage. Finally, in our third objective, we will study whether smoking cessation reduces subclinical and/or predisposition to renal damage., Methods and Analysis: For our first objective, a prospective cross-sectional study will be carried out with patients from a primary healthcare centre. The influence of tobacco on renal damage, in patients both with and without additional risk factors, will be studied using a panel of early biomarkers (albuminuria, N-acetyl-beta-D-glucosaminidase, kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin). For our second objective, a prospective longitudinal study will be carried out with patients recruited for our first objective. We will study whether certain predisposition biomarkers (GM2AP, transferrin and t-gelsolin) are able to detect smokers predisposed to renal damage. For our third objective, a prospective longitudinal study will be carried out with patients from a smoking cessation unit. We will study the evolution of the markers described above following smoking cessation., Ethics and Dissemination: The study has been approved by the Clinical Research Ethics Committee of the Healthcare Area of Salamanca. All study participants will sign an informed consent form in compliance with the Declaration of Helsinki and the WHO standards for observational studies. Results will be presented at conferences and submitted to peer-reviewed journals., Trial Registration Number: NCT03850756., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
49. Urinary transferrin pre-emptively identifies the risk of renal damage posed by subclinical tubular alterations.
- Author
-
Casanova AG, Vicente-Vicente L, Hernández-Sánchez MT, Prieto M, Rihuete MI, Ramis LM, Del Barco E, Cruz JJ, Ortiz A, Cruz-González I, Martínez-Salgado C, Pescador M, López-Hernández FJ, and Morales AI
- Subjects
- Acetylglucosaminidase urine, Animals, Biomarkers urine, Contrast Media adverse effects, Creatinine blood, Disease Susceptibility, Female, Humans, Kidney Diseases chemically induced, Kidney Diseases urine, Lipocalin-2 urine, Male, Middle Aged, Platinum adverse effects, Rats, Wistar, Risk Factors, Urea blood, Kidney Tubules pathology, Transferrin urine
- Abstract
Nephrotoxicity is an important limitation to the clinical use of many drugs and contrast media. Drug nephrotoxicity occurs in acute, subacute and chronic manifestations ranging from glomerular, tubular, vascular and immunological phenotypes to acute kidney injury. Pre-emptive risk assessment of drug nephrotoxicity poses an urgent need of precision medicine to optimize pharmacological therapies and interventional procedures involving nephrotoxic products in a preventive and personalized manner. Biomarkers of risk have been identified in animal models, and risk scores have been proposed, whose clinical use is abated by their reduced applicability to specific etiological models or clinical circumstances. However, our present data suggest that the urinary level of transferrin may be indicative of risk of renal damage, where risk is induced by subclinical tubular alterations regardless of etiology. In fact, urinary transferrin pre-emptively correlates with the subsequent renal damage in animal models in which risk has been induced by drugs and toxins affecting the renal tubules (i.e. cisplatin, gentamicin and uranyl nitrate); whereas transferrin shows no relation with the risk posed by a drug affecting renal hemodynamics (i.e. cyclosporine A). Our experiments also show that transferrin increases in the urine in the risk state (i.e. prior to the damage) precisely as a consequence of reduced tubular reabsorption. Finally, urinary transferrin pre-emptively identifies subpopulations of oncological and cardiac patients at risk of nephrotoxicity. In perspective, urinary transferrin might be further explored as a wider biomarker of an important mechanism of predisposition to renal damage induced by insults causing subclinical tubular alterations., (Copyright © 2019. Published by Elsevier Masson SAS.)
- Published
- 2020
- Full Text
- View/download PDF
50. Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity.
- Author
-
Casanova AG, Hernández-Sánchez MT, López-Hernández FJ, Martínez-Salgado C, Prieto M, Vicente-Vicente L, and Morales AI
- Subjects
- Creatinine blood, Drug-Related Side Effects and Adverse Reactions, Humans, Kidney drug effects, Acute Kidney Injury chemically induced, Acute Kidney Injury epidemiology, Cisplatin adverse effects, Cisplatin pharmacology, Neoplasms drug therapy
- Abstract
Introduction: Cisplatin is a potent antineoplastic drug that has been widely used to treat a number of solid tumors. However, a high incidence of renal damage observed in patients has led researchers to search for alternate strategies that prevent or at least reduce the cisplatin-induced nephrotoxicity. The objective of the present study was to conduct a systematic review and a subsequent meta-analysis to evaluate and identify compounds with effective antitumor activity and lesser side effects that could provide protection against cisplatin-induced nephrotoxicity., Methods: The study included all placebo-controlled trials published up to December 2017 that met the inclusion criteria. A total of 22 articles were finally included to extract the following information: number of patients, doses of cisplatin and protectant, qualitative (acute kidney injury incidence) and quantitative (plasma creatinine, blood urea nitrogen, and creatinine clearance) indicators of renal function. The odds ratio or the mean difference (95% confidence interval) of each parameter was calculated for each study and group of studies., Results: The results of this meta-analysis show that there is great variability in the nephroprotective capacity of a variety of products evaluated. Of all the compounds tested, only magnesium sulfate and cystone were found to exert protective effects. However, more studies need to be conducted to confirm these results., Conclusions: The administration of 1 g of Mg i.v. seems to be the best strategy for the prevention of cisplatin nephrotoxicity.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.